Alprazolam

證據等級: L5

預測適應症: 3 個

Alprazolam: From Anxiety and Panic Disorders to Insomnia

One-Sentence Summary

Alprazolam is a benzodiazepine derivative primarily used for anxiety and panic disorders, acting through positive modulation of GABA-A receptors to produce sedative and anxiolytic effects. The TxGNN model predicts it may be effective for Insomnia, with 7 clinical trials and 18 publications currently supporting this direction. However, most clinical trial evidence is indirect, and the primary pharmacological basis rests on alprazolam’s established sedative-hypnotic properties rather than dedicated insomnia indication trials.

Quick Overview

Item	Content
Original Indication	Anxiety and panic disorders (NPRA approved indication text not retrievable from current data)
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.81%
Evidence Level	L3
Malaysia Market Status	✓ Marketed
Number of Registrations	14
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Alprazolam positively modulates GABA-A receptor chloride ion channels, enhancing inhibitory GABAergic neurotransmission across the central nervous system. This mechanism produces dose-dependent sedation and hypnotic effects — specifically shortening sleep-onset latency and increasing total sleep time — which directly underpins the TxGNN model’s prediction of efficacy in insomnia. The drug’s rapid onset of action (Tmax 1–2 hours) further supports its pharmacological plausibility as a sleep-onset aid.

The mechanistic overlap between anxiety management and sleep induction is clinically well-recognised: anxiety-driven hyperarousal is a leading cause of sleep-onset insomnia, and alprazolam’s dual anxiolytic-sedative profile makes it pharmacologically rational for patients with comorbid anxiety and insomnia. Comparative studies in specialty populations (e.g., haemodialysis patients with end-stage renal disease) have demonstrated alprazolam’s ability to improve subjective and objective sleep quality metrics, lending real-world support to the model prediction.

Nonetheless, important mechanistic limitations must be acknowledged. Alprazolam’s half-life of 6–27 hours raises concern for next-day residual sedation (“hangover effect”), unlike ultra-short-acting benzodiazepines such as triazolam. More critically, long-term use suppresses slow-wave sleep and REM sleep architecture, potentially worsening overall sleep quality over time. These pharmacokinetic and pharmacodynamic constraints mean that while the TxGNN prediction is mechanistically sound, alprazolam is not considered an optimal first-line hypnotic agent under current sleep medicine guidelines.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02648776	N/A	Unknown	1,400	Prospective cohort in Taiwan examining risks and benefits of hypnotics — including benzodiazepines — in elderly patients with sleep disorders; covers alprazolam-relevant patient population and evaluates clinical, pharmacokinetic, and pharmacogenetic outcomes
NCT00266409	Phase 4	Completed	418	Multicenter open-label RCT comparing Niravam™ (alprazolam orally disintegrating tablet) added to a newly prescribed SSRI/SNRI vs SSRI/SNRI alone in patients with GAD or panic disorder; evaluates time to symptomatic response
NCT01584440	Phase 2	Completed	220	Randomised double-blind placebo-controlled trial of AVP-923 (dextromethorphan/quinidine) for agitation in Alzheimer’s disease; provides context for CNS-active drug assessment in elderly patients with sleep-behaviour overlap
NCT04572750	N/A	Completed	170	Electronic self-management intervention to promote benzodiazepine cessation among Veterans; contextualises long-term BZD risks including dependence and cognitive effects of alprazolam class
NCT03327506	Phase 4	Unknown	128	Hypnosis versus alprazolam premedication for perioperative anxiety in gynaecological surgery; alprazolam used as active pharmacological comparator for acute anxiolytic-sedative effect
NCT01146600	Phase 2	Completed	26	Clarithromycin for treatment of hypersomnia; inverse sleep condition study providing mechanistic contrast relevant to GABAergic sleep modulation
NCT01893632	Phase 2	Terminated	2	Gabapentin for benzodiazepine dependence; terminated early due to insufficient enrolment (n=2); provides class-level dependence management context

Note: No clinical trials directly evaluating alprazolam as a primary investigational treatment for insomnia were identified in ClinicalTrials.gov. The above trials provide indirect evidence through hypnotic drug class context, alprazolam as comparator, or BZD risk characterisation in populations with sleep disorders.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33403184	2020	Comparative RCT	Cureus	Head-to-head comparison of alprazolam vs melatonin for sleep disorders in haemodialysis patients; directly evaluates alprazolam efficacy for improving subjective and objective sleep quality in ESRD
39183410	2024	RCT (Integrative Therapy)	Medicine	Alprazolam used as active control in 116 patients with comorbid coronary heart disease and insomnia; experimental group received Du Meridian moxibustion + ear acupuncture; demonstrates alprazolam’s real-world role as a standard-of-care comparator for insomnia
36692463	2023	Meta-analysis	Acta Pharmaceutica (Zagreb)	Systematic review and meta-analysis of randomised and observational studies on tranquilisers (including BZDs) in elderly patients with chronic diseases; assesses optimal dose, type, efficacy outcomes, and adverse effect profiles
37801512	2023	Preclinical Study	Aging	Proteomic analysis in mice showing repeated alprazolam administration causes hippocampal mitochondrial dysfunction and memory consolidation impairment; reveals molecular mechanisms underlying long-term cognitive safety concerns
37984023	2024	Epidemiological Analysis	Value in Health Regional Issues	10-year predictive model of benzodiazepine use trends; documents BZD prescription for insomnia alongside anxiety and mood disorders, and quantifies long-term risks including Alzheimer’s disease, dependence, falls, and traffic accidents
38363887	2024	Cross-sectional Study	Medicine	Cross-sectional study of insomnia prevalence and risk factors in COVID-19 survivors (Dec 2022–Feb 2023); contextualises the contemporary rise in insomnia burden and treatment demand
25532388	2014	Real-world Analysis	China Journal of Chinese Materia Medica	Real-world analysis of 1,067 insomnia patients from 20 Chinese hospitals; maps concurrent disease patterns (hypertension 26.9%, cerebrovascular disease) and medication use including Western hypnotics (benzodiazepine class)
15341891	2004	Observational Study	Sleep Medicine	Large managed-care prescription pattern analysis for insomnia treatment; documents decline in dedicated hypnotic use over a decade and corresponding increase in non-hypnotic prescribing including benzodiazepines for insomnia
23330992	2013	Pharmacology Review	Expert Opinion on Drug Metabolism & Toxicology	Comprehensive review of anxiolytic drug pharmacokinetics; covers alprazolam absorption, distribution, half-life variability (6–27 hours), and clinical implications for daytime residual effects
35041261	2022	RCT	Brain and Behavior	Randomised controlled trial of eszopiclone for sleep quality and cognitive function in elderly Alzheimer’s patients with sleep disorders; provides comparative hypnotic class context for evaluating non-BZD alternatives

Malaysia Market Information

NPRA registration data confirms 14 product authorisations for alprazolam in Malaysia, and the drug is currently marketed. However, individual product details — including authorisation numbers, product names, dosage forms, manufacturers, and approved indication text — were not returned in the current NPRA data extract.

Data Note: Detailed product registration records were not available from the NPRA query at this time. Direct verification via the NPRA official product registry is required to confirm currently approved indications, registered dosage forms, and marketing authorisation holders.

Safety Considerations

Formal warning and contraindication data from the NPRA package insert were not available for this evaluation. Please refer to the registered package insert for complete safety information.

Based on well-established evidence from the published literature and the drug class profile, the following safety considerations are relevant for clinical decision-making:

Dependence and withdrawal: Long-term benzodiazepine use carries significant risk of physical dependence; abrupt discontinuation can precipitate withdrawal seizures and rebound anxiety/insomnia
CNS depression: Drowsiness, psychomotor slowing, and cognitive impairment are common, particularly in elderly patients
Falls and fractures: Elevated risk of falls in older adults, especially in the elderly population
Sleep architecture disruption: Chronic use suppresses slow-wave sleep (SWS) and REM sleep, potentially worsening long-term sleep quality
Respiratory depression: Potentially serious risk when combined with opioids, alcohol, or other CNS depressants
Memory impairment: Anterograde amnesia and hippocampus-dependent memory consolidation deficits documented in both human and animal studies

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Alprazolam’s GABA-A receptor mechanism provides a pharmacologically sound basis for sedative-hypnotic activity in insomnia, and L3-level evidence from observational studies and comparative real-world trials confirms its use for sleep disturbances in clinical practice. However, no dedicated Phase 2/3 RCT for alprazolam in primary insomnia has been identified, long-term use is associated with sleep architecture deterioration and dependence risk, and alprazolam is not recommended as a first-line hypnotic under current international guidelines.

To proceed, the following is needed:

Retrieve NPRA-approved indication text to confirm whether insomnia or sleep disorders are already listed as a registered indication in Malaysia
Obtain the full registered package insert for complete warning, contraindication, and drug interaction data
Clarify the regulatory status of alprazolam as a scheduled/controlled substance in Malaysia and applicable prescription restrictions
Commission a systematic review or meta-analysis specifically for alprazolam in primary insomnia to establish whether L2 evidence can be documented
Design a pharmacovigilance monitoring plan addressing dependence risk, cognitive effects, and falls — particularly for elderly patients and those with renal or hepatic impairment
Define clinical positioning relative to guideline-recommended first-line insomnia treatments (Cognitive Behavioural Therapy for Insomnia [CBT-I], non-benzodiazepine hypnotics such as zolpidem or eszopiclone) to determine where alprazolam adds clinical value
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.